STOCK TITAN

Lifeway Foods (LWAY) boosts H1 2026 sales to $129.9M amid cost pressure

(High)
(Neutral)
Form Type
10-Q

Rhea-AI Filing Summary

Lifeway Foods, Inc. reported strong top-line growth but weaker profitability for the quarter and six months ended June 30, 2026. Net sales rose to $66.9M for the quarter, up 24.1% year over year, and to $129.9M for the first half, a 29.9% increase, primarily from higher volumes of branded drinkable kefir.

Profitability contracted as gross margin fell to 19.5% from 28.6% in the quarter and to 23.4% from 26.5% year to date, driven mainly by higher conventional milk prices and, to a lesser extent, higher resin-based packaging and transportation costs. Quarterly net income declined to $0.1M (basic EPS $0.01) from $4.2M, while six‑month net income decreased to $4.8M from $7.8M.

The company is investing heavily in capacity, with $19.5M of capital expenditures in the first half and an estimated $50.5M project to expand and modernize its Waukesha, Wisconsin plant, expected to double manufacturing capacity. To support this, Lifeway drew $22.0M on its $25.0M revolving credit facility and put in place a $22.0M Interim Funding Agreement for equipment financing, while ending the period with $7.1M in cash and remaining covenant compliant.

Positive

  • Net sales grew 29.9% year over year to $129.9M for the first half of 2026, driven primarily by higher volumes of branded drinkable kefir.
  • Waukesha plant expansion of $50.5M is expected to double manufacturing capacity and improve packaging efficiency, supporting future volume growth.
  • Liquidity remains solid with $7.1M cash, $22.0M drawn on a $25.0M revolver, and $22.0M available under a new Interim Funding Agreement, while remaining in covenant compliance.
  • Shareholder rights plan was redeemed, terminating the Rights Agreement and simplifying the capital structure with a nominal $0.001 per Right redemption.
  • Targeted share repurchase of 253,153 shares for $4.9M in connection with the Danone secondary offering reduced treasury stock and may signal confidence in the business.

Negative

  • Gross margin compressed to 19.5% from 28.6% in the quarter and to 23.4% from 26.5% year to date, mainly from higher milk and packaging costs.
  • Quarterly net income fell sharply to $0.1M (EPS $0.01) from $4.2M (EPS $0.28), with net margin dropping to 0.2%.
  • Interest expense increased significantly to $0.3M year to date from $0.04M, reflecting higher revolver borrowings and adding pressure to earnings.
  • Heavy capital spending of $19.5M and a total $50.5M Waukesha project materially increased investment needs, raising execution and return-on-investment risk.
  • Leverage rose with $22.0M outstanding on the revolving credit facility, introducing higher financial risk if margins remain compressed.

Filing Explained

The shareholder rights ended, while the new $22 million equipment-financing capacity had produced no advances by June 30.

This Form 10-Q is an unaudited quarterly report covering the period ended June 30, 2026; it reports the company’s current financing, capital-spending, and ownership-related mechanics. The May 19, 2026 offering of 3,454,756 common shares by Danone was completed, so ownership shifted to buyers rather than through a new company share issuance; Lifeway received no proceeds and repurchased 253,153 shares at $19.50.

The offering used an effective Form S-3 and a prospectus supplement: the S-3 provided registration capacity, while the supplement supplied the terms of this specific sale. On June 5, 2026, Lifeway also redeemed its shareholder rights for $0.001 per right, terminating both the rights and the rights agreement.

As of June 30, 2026, no advances had been drawn under the $22,000,000 Interim Funding Agreement, while the revolving facility still had availability. The interim capacity is therefore financing availability rather than borrowed funds, and advances remain subject to the lender’s acceptance of collateral documentation.

The company states that increased manufacturing and packaging capacity is expected to begin in January 2027, with the project expected to be completed in the first fiscal quarter of 2027; subsequent filings should show whether available financing becomes borrowed funds and whether the project reaches those milestones.

Q2 2026 Net Sales $66,893 Net sales for the three months ended June 30, 2026
H1 2026 Net Sales $129,905 Net sales for the six months ended June 30, 2026
Q2 2026 Net Income $127 Net income for the three months ended June 30, 2026
H1 2026 Net Income $4,801 Net income for the six months ended June 30, 2026
Total Assets $132,399 Total assets as of June 30, 2026
Revolver Outstanding $22,000 Outstanding under Revolving Credit Facility as of June 30, 2026
Waukesha Project Estimate $50,500 Estimated total investment for Waukesha facility expansion and modernization
Treasury Stock Repurchase $4,937 Cash used to repurchase 253,153 shares in 2026
Revolving Credit Facility financial
"As of June 30, 2026, the Company had $22,000 outstanding under the Revolving Credit Facility"
A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.
Interim Funding Agreement financial
"loan advances under an Interim Funding Agreement to finance or refinance the acquisition of equipment"
Fixed charge coverage ratio financial
"requiring the Company to maintain a fixed charge coverage ratio of no less than 1.25 to 1.00"
A fixed charge coverage ratio measures how well a company's operating income can cover its fixed, recurring obligations like interest payments and lease costs. Think of it as a safety margin — the higher the number, the more comfortably a business can pay steady bills from its normal earnings, which matters to investors because it signals financial stability, lower default risk, and greater ability to withstand revenue dips.
Drinkable kefir technical
"Lifeway’s primary product is drinkable kefir, a cultured dairy product"
Performance units financial
"Performance unit awards are granted to certain members of management"
Performance units are company awards that become valuable only if specified business targets are met; they typically convert into shares or cash when performance goals are achieved. Think of them like a conditional bonus that turns into stock only if the company hits agreed milestones, so they align managers’ incentives with shareholders’ interests and can affect future share count, executive pay expense, and investor returns.
Shareholder Rights Agreement regulatory
"rights of shareholders outstanding to a dividend of Series A Junior Participating Preferred Stock"
A shareholder rights agreement is a legal contract that spells out the powers and protections of shareholders, such as how shares can be bought, sold, or diluted and what happens during takeovers or corporate disputes. It matters to investors because it shapes how much control they have, how their ownership can change, and what safeguards exist against abrupt changes—like a homeowner’s rules that prevent a single neighbor from altering the whole block.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How did Lifeway Foods (LWAY) perform financially in Q2 2026?

Lifeway Foods reported Q2 2026 net sales of $66.9M, up 24.1% year over year, but net income declined to $0.1M from $4.2M. Margin pressure from higher milk, packaging, and transport costs offset strong volume growth in branded drinkable kefir.

What were Lifeway Foods (LWAY) results for the first half of 2026?

For the first half of 2026, Lifeway generated $129.9M in net sales, a 29.9% increase, and $4.8M in net income, down from $7.8M. Gross margin fell to 23.4% as commodity and packaging cost inflation outpaced the benefit from higher volumes.

How is Lifeway Foods (LWAY) funding its Waukesha, Wisconsin expansion?

Lifeway plans to invest $50.5M to expand and modernize its Waukesha facility, with $38.9M invested by June 30, 2026. Funding comes from operating cash flow, cash on hand, a $25.0M revolving credit facility, and a $22.0M Interim Funding Agreement.

What is Lifeway Foods’ (LWAY) current debt and liquidity position?

As of June 30, 2026, Lifeway had $22.0M outstanding on its revolving credit facility, with $3.0M still available, plus $22.0M available under an Interim Funding Agreement and $7.1M in cash. The company reports compliance with all financial covenants.

How did commodity costs affect Lifeway Foods (LWAY) margins in 2026?

Higher conventional milk prices, along with increased resin-based packaging and transportation costs, reduced Lifeway’s gross margin to 19.5% in Q2 2026 and 23.4% year to date. Management expects elevated milk pricing into Q3 2026 before easing in Q4.

What happened in the Danone secondary offering involving Lifeway Foods (LWAY)?

In May 2026, a selling stockholder, Danone USA Public Benefit Corporation, sold 3,454,756 Lifeway shares at $19.50 per share. Lifeway received no proceeds but repurchased 253,153 shares in the offering, spending about $4.9M on treasury stock.

Did Lifeway Foods (LWAY) change its shareholder rights plan in 2026?

Yes. On June 5, 2026, Lifeway’s board redeemed the outstanding rights under its Shareholder Rights Agreement for $0.001 per Right. After redemption, the Rights terminated and the Rights Agreement ceased to have further effect.
false --12-31 Q2 2026 0000814586 1 1 0000814586 2026-01-01 2026-06-30 0000814586 LWAY:CommonStockNoParValueMember 2026-01-01 2026-06-30 0000814586 LWAY:PreferredStockPurchaseRightsMember 2026-01-01 2026-06-30 0000814586 2026-08-07 0000814586 2026-06-30 0000814586 2025-12-31 0000814586 2026-04-01 2026-06-30 0000814586 2025-04-01 2025-06-30 0000814586 2025-01-01 2025-06-30 0000814586 us-gaap:CommonStockMember 2024-12-31 0000814586 us-gaap:TreasuryStockCommonMember 2024-12-31 0000814586 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000814586 us-gaap:RetainedEarningsMember 2024-12-31 0000814586 2024-12-31 0000814586 us-gaap:CommonStockMember 2025-03-31 0000814586 us-gaap:TreasuryStockCommonMember 2025-03-31 0000814586 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000814586 us-gaap:RetainedEarningsMember 2025-03-31 0000814586 2025-03-31 0000814586 us-gaap:CommonStockMember 2025-12-31 0000814586 us-gaap:TreasuryStockCommonMember 2025-12-31 0000814586 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000814586 us-gaap:RetainedEarningsMember 2025-12-31 0000814586 us-gaap:CommonStockMember 2026-03-31 0000814586 us-gaap:TreasuryStockCommonMember 2026-03-31 0000814586 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000814586 us-gaap:RetainedEarningsMember 2026-03-31 0000814586 2026-03-31 0000814586 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000814586 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000814586 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000814586 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000814586 2025-01-01 2025-03-31 0000814586 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000814586 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0000814586 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000814586 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000814586 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000814586 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0000814586 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000814586 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000814586 2026-01-01 2026-03-31 0000814586 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000814586 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0000814586 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000814586 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000814586 us-gaap:CommonStockMember 2025-06-30 0000814586 us-gaap:TreasuryStockCommonMember 2025-06-30 0000814586 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000814586 us-gaap:RetainedEarningsMember 2025-06-30 0000814586 2025-06-30 0000814586 us-gaap:CommonStockMember 2026-06-30 0000814586 us-gaap:TreasuryStockCommonMember 2026-06-30 0000814586 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000814586 us-gaap:RetainedEarningsMember 2026-06-30 0000814586 us-gaap:LandMember 2026-06-30 0000814586 us-gaap:LandMember 2025-12-31 0000814586 LWAY:BuildingsAndImprovementsMember 2026-06-30 0000814586 LWAY:BuildingsAndImprovementsMember 2025-12-31 0000814586 us-gaap:MachineryAndEquipmentMember 2026-06-30 0000814586 us-gaap:MachineryAndEquipmentMember 2025-12-31 0000814586 us-gaap:VehiclesMember 2026-06-30 0000814586 us-gaap:VehiclesMember 2025-12-31 0000814586 us-gaap:OfficeEquipmentMember 2026-06-30 0000814586 us-gaap:OfficeEquipmentMember 2025-12-31 0000814586 us-gaap:ConstructionInProgressMember 2026-06-30 0000814586 us-gaap:ConstructionInProgressMember 2025-12-31 0000814586 LWAY:RecipesMember 2026-06-30 0000814586 LWAY:RecipesMember 2025-12-31 0000814586 LWAY:CustomerListsAndOtherCustomerRelatedIntangiblesMember 2026-06-30 0000814586 LWAY:CustomerListsAndOtherCustomerRelatedIntangiblesMember 2025-12-31 0000814586 us-gaap:CustomerRelationshipsMember 2026-06-30 0000814586 us-gaap:CustomerRelationshipsMember 2025-12-31 0000814586 LWAY:BrandNamesMember 2026-06-30 0000814586 LWAY:BrandNamesMember 2025-12-31 0000814586 LWAY:FormulaMember 2026-06-30 0000814586 LWAY:FormulaMember 2025-12-31 0000814586 us-gaap:CustomerRelationshipsMember 2026-01-01 2026-06-30 0000814586 LWAY:BrandNamesMember 2026-01-01 2026-06-30 0000814586 us-gaap:RevolvingCreditFacilityMember 2026-06-30 0000814586 us-gaap:RevolvingCreditFacilityMember 2026-01-01 2026-06-30 0000814586 LWAY:MasterSecurityAgreementMember 2026-06-30 0000814586 LWAY:MasterSecurityAgreementMember 2026-01-01 2026-06-30 0000814586 LWAY:OmnibusIncentivePlan2022Member 2026-06-30 0000814586 LWAY:DirectorPlan2022Member 2026-06-30 0000814586 us-gaap:RestrictedStockUnitsRSUMember 2026-06-30 0000814586 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-06-30 0000814586 us-gaap:PerformanceSharesMember 2026-06-30 0000814586 us-gaap:PerformanceSharesMember 2026-01-01 2026-06-30 0000814586 LWAY:DefinedContributionPlanMember 2026-01-01 2026-06-30 0000814586 LWAY:DefinedContributionPlanMember 2025-01-01 2025-06-30 0000814586 LWAY:DefinedContributionPlanMember 2026-04-01 2026-06-30 0000814586 LWAY:DefinedContributionPlanMember 2025-04-01 2025-06-30 0000814586 us-gaap:StockOptionMember 2025-12-31 0000814586 us-gaap:StockOptionMember 2026-01-01 2026-06-30 0000814586 us-gaap:StockOptionMember 2026-06-30 0000814586 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0000814586 us-gaap:PerformanceSharesMember 2025-12-31 0000814586 us-gaap:SalesRevenueNetMember LWAY:TwoCustomersMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000814586 us-gaap:SalesRevenueNetMember LWAY:TwoCustomersMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0000814586 us-gaap:SalesRevenueNetMember LWAY:TwoCustomersMember us-gaap:CustomerConcentrationRiskMember 2026-04-01 2026-06-30 0000814586 us-gaap:SalesRevenueNetMember LWAY:TwoCustomersMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0000814586 LWAY:DrinkableKefirMember 2026-01-01 2026-06-30 0000814586 LWAY:DrinkableKefirMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000814586 LWAY:DrinkableKefirMember 2025-01-01 2025-06-30 0000814586 LWAY:DrinkableKefirMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0000814586 LWAY:CheeseMember 2026-01-01 2026-06-30 0000814586 LWAY:CheeseMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000814586 LWAY:CheeseMember 2025-01-01 2025-06-30 0000814586 LWAY:CheeseMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0000814586 LWAY:CreamAndOtherMember 2026-01-01 2026-06-30 0000814586 LWAY:CreamAndOtherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000814586 LWAY:CreamAndOtherMember 2025-01-01 2025-06-30 0000814586 LWAY:CreamAndOtherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0000814586 LWAY:DrinkableYogurtMember 2026-01-01 2026-06-30 0000814586 LWAY:DrinkableYogurtMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000814586 LWAY:DrinkableYogurtMember 2025-01-01 2025-06-30 0000814586 LWAY:DrinkableYogurtMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0000814586 LWAY:OtherDairyMember 2026-01-01 2026-06-30 0000814586 LWAY:OtherDairyMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000814586 LWAY:OtherDairyMember 2025-01-01 2025-06-30 0000814586 LWAY:OtherDairyMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0000814586 LWAY:NetSalesMember 2026-01-01 2026-06-30 0000814586 LWAY:NetSalesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000814586 LWAY:NetSalesMember 2025-01-01 2025-06-30 0000814586 LWAY:NetSalesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0000814586 LWAY:DrinkableKefirMember 2026-04-01 2026-06-30 0000814586 LWAY:DrinkableKefirMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-04-01 2026-06-30 0000814586 LWAY:DrinkableKefirMember 2025-04-01 2025-06-30 0000814586 LWAY:DrinkableKefirMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0000814586 LWAY:CheeseMember 2026-04-01 2026-06-30 0000814586 LWAY:CheeseMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-04-01 2026-06-30 0000814586 LWAY:CheeseMember 2025-04-01 2025-06-30 0000814586 LWAY:CheeseMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0000814586 LWAY:CreamAndOtherMember 2026-04-01 2026-06-30 0000814586 LWAY:CreamAndOtherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-04-01 2026-06-30 0000814586 LWAY:CreamAndOtherMember 2025-04-01 2025-06-30 0000814586 LWAY:CreamAndOtherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0000814586 LWAY:DrinkableYogurtMember 2026-04-01 2026-06-30 0000814586 LWAY:DrinkableYogurtMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-04-01 2026-06-30 0000814586 LWAY:DrinkableYogurtMember 2025-04-01 2025-06-30 0000814586 LWAY:DrinkableYogurtMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0000814586 LWAY:OtherDairyMember 2026-04-01 2026-06-30 0000814586 LWAY:OtherDairyMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-04-01 2026-06-30 0000814586 LWAY:OtherDairyMember 2025-04-01 2025-06-30 0000814586 LWAY:OtherDairyMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0000814586 LWAY:NetSalesMember 2026-04-01 2026-06-30 0000814586 LWAY:NetSalesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-04-01 2026-06-30 0000814586 LWAY:NetSalesMember 2025-04-01 2025-06-30 0000814586 LWAY:NetSalesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0000814586 2026-06-05 0000814586 2025-01-01 2025-12-31 0000814586 LWAY:HerdAgreementMember 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure LWAY:Cows LWAY:Integer

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

       QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: June 30, 2026

 

       TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number: 001-42398

 

LIFEWAY FOODS, INC.

(Exact name of registrant as specified in its charter)

 

Illinois 36-3442829

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

6431 West Oakton, Morton Grove, IL 60053

(Address of principal executive offices, zip code)

 

(847) 967-1010

(Registrant’s telephone number, including area code)

 

Securities registered under Section 12(b) of the Exchange Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, No Par Value LWAY Nasdaq Global Market
Preferred Stock Purchase Rights None Nasdaq Global Market

 

Securities registered under Section 12(g) of the Exchange Act:

None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

 

  Large accelerated Filer ☐ Accelerated Filer ☐
  Non-accelerated Filer Smaller reporting company
  Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Number of shares of Common Stock, no par value, outstanding as of August 7, 2026: 15,106,747.

 

 

   

 

 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION  
   
Item 1. Financial Statements. 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 19
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 26
Item 4. Controls and Procedures. 26
   
PART II – OTHER INFORMATION  
   
Item 1. Legal Proceedings. 27
Item 1A. Risk Factors. 27
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 27
Item 3. Defaults Upon Senior Securities. 27
Item 5. Other Information. 27
Item 6. Exhibits. 28
  Signatures. 29

 

 

  

 

 

 

 2 

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

LIFEWAY FOODS, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

June 30, 2026 and December 31, 2025

(In thousands)

         
   June 30, 2026   December 31, 
   (Unaudited)   2025 
Current assets          
Cash and cash equivalents  $7,087   $5,571 
Accounts receivable, net of allowance for credit losses and discounts & allowances of $2,800 and $1,730 at June 30, 2026 and December 31, 2025, respectively   22,861    16,643 
Inventories, net   13,987    11,890 
Prepaid expenses and other current assets   2,526    2,627 
Refundable income taxes   728    325 
Total current assets   47,189    37,056 
           
Property, plant and equipment, net   65,596    48,282 
Operating lease right-of-use asset   521    465 
Goodwill   11,704    11,704 
Intangible assets, net   5,548    5,818 
Other assets   1,841    2,285 
Total assets  $132,399   $105,610 
           
Current liabilities          
Accounts payable  $17,483   $11,008 
Accrued expenses   4,745    5,413 
Accrued income taxes   304    218 
Total current liabilities   22,532    16,639 
           
Line of credit   21,945     
Operating lease liabilities   393    360 
Deferred income taxes, net   2,792    2,792 
Other long-term liabilities   163     
Total liabilities   47,825    19,791 
           
Commitments and contingencies (Note 9)        
           
Stockholders’ equity          
Preferred stock, no par value; 2,500 shares authorized; none issued        
Common stock, no par value; 40,000 shares authorized; 17,274 shares issued; 15,105 and 15,232 outstanding at June 30, 2026 and December 31, 2025, respectively   6,509    6,509 
Treasury stock, at cost   (17,217)   (13,214)
Paid-in capital   1,800    3,843 
Retained earnings   93,482    88,681 
Total stockholders’ equity   84,574    85,819 
           
Total liabilities and stockholders’ equity  $132,399   $105,610 

 

See accompanying notes to consolidated financial statements

 

 

 

 3 

 

 

LIFEWAY FOODS, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

For the three and six months ended June 30, 2026 and 2025

(Unaudited)

(In thousands, except per share data)

                 
  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
   2026   2025   2026   2025 
                 
Net sales  $66,893   $53,901   $129,905   $99,992 
                     
Cost of goods sold   52,859    37,669    97,600    71,923 
Depreciation expense   1,008    832    1,928    1,634 
Total cost of goods sold   53,867    38,501    99,528    73,557 
                     
Gross profit   13,026    15,400    30,377    26,435 
                     
Selling expense   7,634    4,718    13,822    9,416 
General and administrative expense   4,657    4,752    9,360    9,380 
Amortization expense   135    135    270    270 
Total operating expenses   12,426    9,605    23,452    19,066 
                     
Income from operations   600    5,795    6,925    7,369 
                     
Other income (expense):                    
Interest expense   (215)   (21)   (283)   (35)
Fair Value Loss on investments               (20)
Gain on sale of investments       55        3,407 
Other income (expense), net   22    82    22    156 
Total other income (expense)   (193)   116    (261)   3,508 
                     
Income before provision for income taxes   407    5,911    6,664    10,877 
                     
Provision for income taxes   280    1,662    1,863    3,088 
                     
Net income  $127   $4,249   $4,801   $7,789 
                     
Net earnings per common share:                    
Basic  $0.01   $0.28   $0.32   $0.51 
Diluted  $0.01   $0.28   $0.31   $0.51 
                     
Weighted average common shares outstanding:                    
Basic   15,161    15,206    15,209    15,170 
Diluted   15,289    15,390    15,334    15,359 

 

See accompanying notes to consolidated financial statements

 

 

 

 4 

 

 

LIFEWAY FOODS, INC. AND SUBSIDIARIES

Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands)

                             
   Common Stock             
   Issued   In treasury   Paid-In   Retained   Total 
   Shares   $   Shares   $   Capital   Earnings   Equity 
Balance, January 1, 2025   17,274   $6,509    (2,174)  $(14,052)  $4,632   $74,822   $71,911 
                                    
Issuance of Common Stock           103    669    (2,278)       (1,609)
                                    
Stock-based compensation                   326        326 
                                    
Net income                       3,540    3,540 
                                    
Balance, March 31, 2025   17,274   $6,509    (2,071)  $(13,383)  $2,680   $78,362   $74,168 
                                    
Issuance of common stock in connection with stock-based compensation           18    115    (437)       (322)
                                    
Stock-based compensation                   601        601 
                                    
Net income                       4,249    4,249 
                                    
Balance, June 30, 2025   17,274   $6,509    (2,053)  $(13,268)  $2,844   $82,611   $78,696 

 

                             
   Common Stock             
   Issued   In treasury   Paid-In   Retained   Total 
   Shares   $   Shares   $   Capital   Earnings   Equity 
Balance, January 1, 2026   17,274   $6,509    (2,042)  $(13,214)  $3,843   $88,681   $85,819 
                                    
Issuance of common Stock           50    325    (761)       (436)
                                    
Equity award settled in cash                   (283)       (283)
                                    
Stock-based compensation                   548        548 
                                    
Net income                       4,674    4,674 
                                    
Balance, March 31, 2026   17,274   $6,509    (1,992)  $(12,889)  $3,347   $93,355   $90,322 
                                    
Issuance of common Stock           77    609    (2,082)       (1,473)
                                    
Repurchase of common stock           (253)   (4,937)           (4,937)
                                    
Stock-based compensation                   535        535 
                                    
Net income                       127    127 
                                    
Balance, June 30, 2026   17,274   $6,509    (2,168)  $(17,217)  $1,800   $93,482   $84,574 

 

See accompanying notes to consolidated financial statements

 

 

 

 5 

 

 

LIFEWAY FOODS, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

         
   Six months ended June 30, 
   2026   2025 
Cash flows from operating activities:          
Net income  $4,801   $7,789 
Adjustments to reconcile net income to operating cash flow:          
Depreciation and amortization   2,198    1,904 
Stock-based compensation   1,083    927 
Non-cash interest expense   11    9 
Bad debt expense   87     
Gain on sale of equipment   (19)   (115)
Gain on sale of investments       (3,407)
Fair value loss on investment       20 
(Increase) decrease in operating assets:          
Accounts receivable   (6,305)   (640)
Inventories   (2,097)   (1,546)
Prepaid expenses and other current assets   297    322 
Refundable income taxes   (404)   631 
Increase (decrease) in operating liabilities:          
Accounts payable   6,739    500 
Accrued expenses   (2,601)   (2,632)
Accrued income taxes   86     
Other long-term liabilities   163     
Net cash provided by operating activities   4,039    3,762 
           
Cash flows from investing activities:          
Purchases of property and equipment   (19,505)   (4,526)
Proceeds from sale of equipment   223    115 
Proceeds from sale of investments       5,206 
Net cash (used in) provided by investing activities   (19,282)   795 
           
Cash flows from financing activities:          
Purchase of treasury stock   (4,937)    
Borrowings under line of credit   23,000     
Repayments under line of credit   (1,000)    
Payment of deferred financing costs   (21)   (65)
Equity award settled in cash   (283)    
Net cash provided by (used in) financing activities   16,759    (65)
           
Net increase in cash and cash equivalents   1,516    4,492 
           
Cash and cash equivalents at the beginning of the period   5,571    16,728 
           
Cash and cash equivalents at the end of the period  $7,087   $21,220 
           
Supplemental cash flow information:          
Cash paid for income taxes, net of (refunds)  $2,180   $2,457 
Cash paid for interest  $200   $26 
           
Non-cash investing activities          
Accrued purchase of property and equipment  $512   $1,083 
Right-of-use assets obtained in exchange for lease obligations  $119   $196 

 

See accompanying notes to consolidated financial statements

 

 

 6 

 

 

LIFEWAY FOODS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(Unaudited)

(In thousands, except per share data)

 

 

Note 1 – Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) for interim financial information, and do not include certain information and footnote disclosures required for complete, audited financial statements. In the opinion of management, these statements include all adjustments necessary for a fair presentation of the results of all interim periods reported herein. The consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Results of operations for any interim period are not necessarily indicative of future or annual results.

 

Principles of consolidation

 

The consolidated financial statements include the accounts of Lifeway Foods, Inc. and all its wholly owned subsidiaries (collectively “Lifeway” or the “Company”). All significant intercompany accounts and transactions have been eliminated.

 

Note 2 – Summary of Significant Accounting Policies

 

Our significant accounting policies, which are summarized in detail in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, have not materially changed. The following is a description of certain of our significant accounting policies.

 

Use of estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made in preparing the consolidated financial statements include the reserve for promotional allowances, the valuation of goodwill and intangible assets, stock-based and incentive compensation, and deferred income taxes.

 

Cash and cash equivalents

 

Lifeway considers cash and all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates or equals fair value due to their short-term nature.

 

Lifeway from time to time may have bank deposits in excess of insurance limits of the Federal Deposit Insurance Corporation. The Company places its cash and cash equivalents with high credit quality financial institutions. Lifeway has not experienced any losses in such accounts and believes the financial risks associated with these financial instruments are minimal.

 

 

 

 7 

 

 

Advertising and promotional costs

 

Advertising costs are expensed as incurred and reported in Selling expense in the Company’s consolidated statement of operations. Total advertising expense was $8,162 and $4,418 for the six months ended June 30, 2026 and 2025, respectively. Total advertising expense was $4,787 and $2,282 for the three months ended June 30, 2026 and 2025, respectively.

  

Fair value measurements

 

In February 2025, the Company’s $1,800 equity investment in Simple Mills was liquidated as a result of the sale of Simple Mills. The Company received cash proceeds of $5,206 and recognized a gain on the sale of investment of $3,407 during the six months ended June 30, 2025. The Company received cash proceeds of $54 and recognized a gain on the sale of investment of $54 during the three months ended June 30, 2025.

 

Segments

 

The Company is managed as a single reportable segment. The Chief Executive Officer, who is the Company’s Chief Operating Decision Maker (“CODM”), reviews financial information on an aggregate basis for purposes of allocating resources and assessing financial performance, as well as for making strategic operational decisions and managing the organization. Substantially all of Lifeway’s consolidated revenues relate to the sale of cultured dairy products that it produces using the same processes and materials and are sold to consumers through a common network of distributors and retailers in the United States.

 

Recent accounting pronouncements

 

Issued but not yet effective

 

In November 2024, the Financial Accounting Standards Board (“FASB”) issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Topic 220-40): Disaggregation of Income Statement Expenses. The new standard requires additional disclosure of certain amounts included in the expense captions presented on the Statement of Operations as well as disclosures about selling expenses. The new standard is effective on a prospective basis, with the option for retrospective application, for our annual period ending December 31, 2027, and our interim periods during the fiscal year ending December 31, 2028. The new standard does not affect recognition or measurement in the Company’s consolidated financial statements. Upon adoption, the impact of ASU 2024-03 will be limited to certain notes to the Consolidated Financial Statements.

 

Note 3 – Inventories, net

          
   June 30,
2026
   December 31,
2025
 
Ingredients  $4,299   $4,141 
Packaging   4,324    3,452 
Finished goods   5,364    4,297 
Total inventories, net  $13,987   $11,890 

 

 

 

 8 

 

 

Note 4 – Property, Plant and Equipment, net

          
   June 30,
2026
   December 31,
2025
 
Land  $1,565   $1,565 
Buildings and improvements   32,208    24,497 
Machinery and equipment   43,778    43,433 
Vehicles   477    477 
Office equipment   639    694 
Construction in process   30,903    19,803 
    109,570    90,469 
Less accumulated depreciation   (43,974)   (42,187)
Total property, plant and equipment, net  $65,596   $48,282 

 

Note 5 – Goodwill and Intangible Assets

 

Goodwill

 

Goodwill consisted of the following:

    
   Total 
Balance at December 31, 2025     
Goodwill  $12,948 
Accumulated impairment losses   (1,244)
   $11,704 
     
Balance at June 30, 2026    
Goodwill  $12,948 
Accumulated impairment losses   (1,244)
   $11,704 

 

Intangible Assets

 

Other intangible assets, net consisted of the following:

                
   June 30, 2026   December 31, 2025 
   Gross       Net   Gross       Net 
   Carrying   Accumulated   Carrying   Carrying   Accumulated   Carrying 
   Amount   Amortization   Amount   Amount   Amortization   Amount 
                         
Recipes  $44   $(44)  $   $44   $(44)  $ 
Customer lists and other customer related intangibles   4,529    (4,529)       4,529    (4,529)    
Customer relationships   3,385    (1,772)   1,613    3,385    (1,692)   1,693 
Brand names   7,948    (4,013)   3,935    7,948    (3,823)   4,125 
Formula   438    (438)       438    (438)    
Total intangible assets, net  $16,344   $(10,796)  $5,548   $16,344   $(10,526)  $5,818 

 

 

 

 9 

 

 

Estimated amortization expense on intangible assets for the next five years is as follows:

     
Year  Amortization 
Six months ended December 31, 2026  $270 
2027  $540 
2028  $540 
2029  $540 
2030  $540 

 

The weighted-average remaining amortization expense period for the customer relationship and brand name intangible assets is 10.1 and 10.4 years, respectively, as of June 30, 2026. The weighted-average remaining amortization expense period for total intangible assets is 10.3 years as of June 30, 2026.

  

Note 6 – Accrued Expenses

 

Accrued expenses consisted of the following:

          
   June 30,
2026
  

December 31,

2025

 
Payroll and incentive compensation  $3,533   $4,386 
Real estate taxes   517    483 
Utilities   215    189 
Current portion of operating lease liabilities   128    106 
Other   352    249 
Total accrued expenses  $4,745   $5,413 

 

Note 7 – Debt

 

Revolving Credit Facility

 

On February 5, 2025, the Company entered into the Fifth Modification to the Amended and Restated Loan and Security Agreement (the “Fifth Modification”) with its current lender. The Fifth Modification, among other things, (i) increased the commitment for revolving loans under the Credit Agreement from $5,000 to $25,000, with interest payable at either the lender Base Rate (the Prime Rate minus 1.00%) or the Secured Overnight Financing Rate (“SOFR”) plus 1.75%, (ii) extended the termination date of the Credit Agreement to February 5, 2028, (iii) replaced the quarterly minimum working capital financial covenant with a financial covenant to maintain a maximum cash flow leverage ratio of no greater than 2.00 to 1.00 for each fiscal quarter commencing with the fiscal quarter ending March 31, 2025, (iv) increased the quarterly unused revolving line of credit fee to 0.25%, and (v) increased the letter of credit fee to 1.00%. The remaining material terms and conditions of the Credit Agreement remain substantially unchanged. The Company had no outstanding borrowings at the time of entry into the Fifth Modification.

 

 

 

 10 

 

 

On December 29, 2025, the Company entered into the Sixth Modification to the Amended and Restated Loan and Security Agreement (the “Sixth Modification”) with its current lender. The Sixth Modification, provides for, among other things, (i) modification of the Fixed Charge Coverage Ratio only for the period from December 31, 2025 through June 30, 2027 to exclude the Waukesha, WI unfinanced capital expenditures attributable to plant optimization and manufacturing capacity expansion as approved by lender, up to $50,000 (ii) modification of the Change of Control definition to reflect that specified changes to the Company’s board of directors do not constitute a Change of Control and (iii) extended the termination date of the Credit Agreement to February 5, 2029. The remaining material terms and conditions of the Credit Agreement remain substantially unchanged. The Company had no outstanding borrowings at the time of entry into the Sixth Modification.

 

As of June 30, 2026, the Company had $22,000 outstanding under the Revolving Credit Facility and net unamortized deferred financing costs of $55 related to the Revolving Credit Facility which were included as a direct deduction from the outstanding line of credit. The Company had $3,000 available for future borrowings under the Revolving Credit Facility as of June 30, 2026. Lifeway’s interest rate on debt outstanding under the Revolving Credit Facility as of June 30, 2026 was 5.48%.

 

Interim Funding Agreement

 

On June 30, 2026, the Company entered into a Master Security Agreement (the “MSA”) with its current lender. The MSA provides for loan advances under an Interim Funding Agreement (the “Interim Funding Agreement”) to finance or refinance the acquisition of equipment, subject to lender’s acceptance of collateral documentation, up to $22,000,000 in the aggregate, during an interim funding period which expires June 30, 2027. Interest on the loan advances is payable monthly in arrears at the 1-month Term SOFR plus 1.65%.

 

Upon the conclusion of loan advances under the Interim Funding Agreement, and the execution of a Collateral Schedule by lender and Lifeway, all loan advances outstanding on the date of such Collateral Schedule (the “Conversion Date”), shall be converted into the Equipment Guidance Line Note (the “Note”). The note is payable in monthly installments of principal and interest and matures five years after the Conversion Date. Interest is payable monthly in arrears at the 1-month Term SOFR plus 1.65%.

 

There were no advances outstanding under the Interim Funding Agreement as of June 30, 2026.

 

Lifeway was in compliance with the fixed charge coverage ratio and maximum cash flow leverage ratio covenants at June 30, 2026.

 

Note 8 – Leases

 

The Company leases certain machinery and equipment with fixed base rent payments and variable costs based on usage. Remaining lease terms for these leases range from less than one year to six years. The Company includes lease extension options, if applicable and reasonably certain to be exercised, in the calculation of the right-of-use asset and lease liabilities. Lifeway includes only fixed payments for lease components in the measurement of the right-of-use asset and lease liability. Variable lease payments are those that vary because of changes in facts or circumstances occurring after the commencement date, other than the passage of time. There are no residual value guarantees. Lifeway does not currently have leases which meet the finance lease classification as defined under ASC 842.

 

Lifeway treats contracts as a lease when the contract conveys the right to use a physically distinct asset for a period of time in exchange for consideration, it directs the use of the asset and obtains substantially all the economic benefits of the asset.

  

 

 

 11 

 

 

Right-of-use assets and lease liabilities are measured and recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Lifeway has elected the practical expedient to combine lease and non-lease components into a single component for all of its leases. When the Company is unable to determine an implicit interest rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments for those leases. Lifeway includes options to extend or terminate the lease in the measurement of the right-of-use asset and lease liability when it is reasonably certain that it will exercise such options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

 

The Company does not record leases with an initial term of 12 months or less on the balance sheet. Expense for these short-term leases is recorded on a straight-line basis over the lease term. Total lease expense was $135 and $95 (including short term leases) for the six months ended June 30, 2026 and 2025, respectively. Total lease expense was $73 and $58 (including short term leases) for the three months ended June 30, 2026 and 2025, respectively.

 

Future maturities of lease liabilities were as follows:

    
Year  Operating Leases 
Six months ended December 31, 2026  $87 
2027   169 
2028   153 
2029   106 
2030   78 
Thereafter   41 
Total lease payments   634 
Less: Interest   (113)
Present value of lease liabilities  $521 

 

The weighted-average remaining lease term for its operating leases was 4.1 years as of June 30, 2026. The weighted average discount rate of its operating leases was 9.74% as of June 30, 2026. Cash paid for amounts included in the measurement of lease liabilities was $90 and $47 for the six months ended June 30, 2026 and 2025, respectively. Cash paid for amounts included in the measurement of lease liabilities was $45 and $28 for the three months ended June 30, 2026 and 2025, respectively.

 

Note 9 – Commitments and contingencies

 

Litigation

 

Lifeway is involved in various legal proceedings, claims, disputes, regulatory matters, audits, and proceedings arising in the ordinary course of, or incidental, to the Company’s business, including commercial disputes, product liabilities, intellectual property matters and employment-related matters.

 

Lifeway records provisions in the consolidated financial statements for pending legal matters when it believes it is probable that a loss will be incurred and the amount of such loss can be reasonably estimated. The Company evaluates, on a periodic basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and estimable, it does not establish an accrued liability. Currently, none of its accruals for outstanding legal matters are material individually or in the aggregate to its financial position and it is management’s opinion that the ultimate resolution of these outstanding legal matters will not have a material adverse effect on its business, financial condition, results of operations, or cash flows. However, if the Company is ultimately required to make payments in connection with an adverse outcome, it is possible that such contingency could have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.

 

 

 

 12 

 

 

Note 10 – Income taxes

 

Income taxes were recognized at effective rates of 28.0% and 28.4% for the six months ended June 30, 2026 and 2025, respectively. Income taxes were recognized at effective rates of 68.7% and 28.1% for the three months ended June 30, 2026 and 2025, respectively. Statutory Federal and state tax rates remained consistent from 2025 to 2026. The Company has items that are nondeductible or are discrete adjustments to tax expense. The Company consistently reflects non-deductible officer compensation expense, non-deductible stock-based compensation expense and separate state tax rates from period to period. Although similar items were reflected in the three months ended June 30 , 2026, the percentage effect is different due to the difference in pre-tax income in the three months ended June 30, 2026 compared to the same period in 2025.

 

The Company calculates the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate for the full year, excluding unusual or infrequently occurring discrete items, and applies that rate to income (loss) before provision for income taxes for the period.

 

The Company’s effective tax rate may change from period to period based on recurring and non-recurring factors including the relative mix of pre-tax earnings (or losses), the jurisdictional mix of earnings, enacted tax legislation, state income taxes, the impact of non-deductible items, changes in valuation allowances, settlement of tax audits, and the expiration of the statute of limitations in relation to unrecognized tax benefits. The Company records discrete income tax items such as enacted tax rate changes and completed tax audits in the period in which they occur.

 

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, which includes a broad range of tax reform provisions that may affect the Company’s financial results. The OBBBA changes to corporate taxation include, but are not limited to, 100% bonus depreciation for purchases of qualified property, an elective deduction for domestic research and experimental expenditures, changes to the definition of adjusted taxable income for purposes of determining the interest deduction limitation under Internal Revenue Code Section 163(j), and a more favorable tax rate on Foreign-Derived Deduction Eligible Income and income from non-U.S. subsidiaries (Net CFC Tested Income). The OBBBA does not have a material impact on our estimated annual effective tax rate. Management is assessing the impact on cash flows for the current fiscal year.

 

Note 11 – Stock-based and Other Compensation

 

Employee Incentive and Non-Employee Director Plans

 

The Board of Directors adopted, and the Company’s stockholders approved, the “Lifeway Foods, Inc. 2022 Omnibus Incentive Plan” (the “Plan”). Under the Plan, the Compensation Committee may grant awards of various types of compensation, including nonqualified stock options, incentive stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares, performance units, cash-based awards and other stock-based awards to qualifying employees. The maximum number of shares authorized to be awarded under the Plan is 3.25 million. As of June 30, 2026, 2.57 million shares remain available to award under the Plan.

 

Lifeway stockholders approved the 2022 Non-Employee Director Equity and Deferred Compensation Plan (the “2022 Director Plan”), which authorizes the grant of restricted stock units. The maximum aggregate number of shares that may be issued under the 2022 Director Plan is 500 thousand. As of June 30, 2026, 376 thousand shares remain available to award under the 2022 Director Plan.

 

Total compensation expense related to stock-based payments and the related income tax benefit recognized in net income are as follows:

Schedule of compensation expense related to stock-based payments                
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2026   2025   2026   2025 
   (In Thousands) 
Compensation expense related to stock-based payments  $535   $601   $1,083   $927 
Related income tax benefit   150    168    303    259 

 

 

 

 13 

 

 

Stock Options

 

The following table summarizes stock option activity during the six months ended June 30, 2026:

                
   Options   Weighted
average
exercise price
   Weighted
average
remaining contractual life
   Aggregate
intrinsic value
 
   (In thousands)             
Outstanding at December 31, 2025   13   $9.57    0.49   $193 
Granted                
Exercised                
Forfeited   (13)   9.57         
Outstanding at June 30, 2026      $    0.00   $ 
Exercisable at June 30, 2026      $    0.00   $ 

 

Restricted Stock Units

 

Restricted stock unit awards generally vest in approximately three equal installments on each yearly anniversary of the grant date. Certain non-employee directors have elected to defer receipt of their awards until their departure from the Board of Directors.

 

The following table summarizes restricted stock unit activity during the six months ended June 30, 2026.

        
   Restricted
Stock Units
   Weighted Average Grant Date Fair Value 
   (In thousands)     
Nonvested, at December 31, 2025   171   $11.55 
Granted   9    21.50 
Shares issued upon vesting   (51)   10.58 
Shares settled in cash   (13)   6.25 
Forfeited        
Nonvested, at June 30, 2026   116   $13.38 
Earned and deferred at June 30, 2026   92   $9.98 

 

Unrecognized compensation expense related to nonvested restricted stock units was $559 as of June 30, 2026 and will be recognized over a weighted average period of 0.9 years. The grant date fair value of the awards is equal to the Company’s closing price on the grant date.

 

 

 

 14 

 

 

Performance Units

 

Performance unit awards are granted to certain members of management. These awards include both service and performance conditions.

 

For performance unit awards granted in fiscal years 2024 through 2026, performance goals are established upfront and are measured over a cumulative three-year measurement period. The performance goals are 1) 3-year cumulative net revenue, and 2) 3-year cumulative adjusted EBITDA. The target number of performance unit awards are weighted 50% on net revenue and 50% on adjusted EBITDA. Participants may earn more or less than the target number of units, and are bound by minimum and maximum thresholds of net revenue and adjusted EBITDA. The PSU awards will be earned and will vest, if at all, after the end of the three-year measurement period.

 

The following table summarizes performance unit activity during the six months ended June 30, 2026.

        
   Performance
Units
   Weighted Average Grant Date Fair Value 
   (In thousands)     
Nonvested, at December 31, 2025   199   $12.10 
Granted (1)   70    10.78 
Shares issued upon vesting   (155)   6.88 
Forfeited        
Nonvested, at June 30, 2026   114   $18.43 

 

(1) Includes 51 thousand additional shares granted in connection with the vesting of the 2023 award in 2026 due to above-target performance in accordance with the terms of the award.

 

Unrecognized compensation expense related to nonvested performance units is estimated to be approximately $1,365 as of June 30, 2026 and is expected to be recognized over a weighted average period of 1.1 years. The grant date fair value of the awards is equal to the Company’s closing price on the grant date.

 

Deferred Time-Vested and Performance-Based Cash Awards

 

On March 6, 2026, the Company granted deferred cash awards, consisting of time-vested and performance-based awards, to the Chief Executive Officer and Chief of Staff. These awards were issued as part of the Company’s fiscal-year 2026 long-term incentive program, structured as cash awards to comply with the Company’s contractual obligations applicable at the time of the grant prohibiting the issuance of equity to the Company’s Chief Executive Officer and certain of her affiliates.

 

The deferred time-vested cash awards vest in approximately three equal installments on each yearly anniversary of the grant date.

 

The deferred performance-based cash award performance goals are established upfront and are measured over a cumulative three-year measurement period. The performance goals are 1) 3-year cumulative net revenue, and 2) 3-year cumulative adjusted EBITDA. The target cash awards are weighted 50% on net revenue and 50% on adjusted EBITDA. Participants may earn more or less than the target cash award, and are bound by minimum and maximum thresholds of net revenue and adjusted EBITDA. The deferred performance-based cash awards will be earned and will vest, if at all, after the end of the three-year measurement period.

 

The deferred cash awards may be settled in cash, common stock or a combination of cash and common stock at the discretion of the Company.

 

 

 

 15 

 

 

Retirement Benefits

 

Lifeway has a defined contribution plan which is available to substantially all full-time employees. Under the terms of the plan, the Company matches employee contributions under a prescribed formula. For the six months ended June 30, 2026 and 2025, total contribution expense recognized in the consolidated statements of operations was $473 and $413, respectively. For the three months ended June 30, 2026 and 2025, total contribution expense recognized in the consolidated statements of operations was $222 and $152, respectively.

 

Note 12 - Earnings Per Share

 

The following table summarizes the effects of the share-based compensation awards on the weighted average number of shares outstanding used in calculating diluted earnings per share:

                
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2026   2025   2026   2025 
   (In thousands) 
Weighted average common shares outstanding   15,161    15,206    15,209    15,170 
Assumed exercise/vesting of equity awards   128    184    125    189 
Weighted average diluted common shares outstanding   15,289    15,390    15,334    15,359 

 

Note 13 – Reportable Segments and Disaggregated Revenue

 

The Company has one reportable segment, which manufactures and distributes cultured dairy products. Our products are produced using the same processes and materials and are sold to consumers through a common network of distributors and retailers. The Company derives revenue primarily in North America and manages the business activities on a consolidated basis. The business activities include selling cultured dairy products across various channels including retail-direct, distributor, and direct store delivery in a refrigerated format. We operate our business with a centralized financial systems infrastructure, and we share centralized resources for procurement and general and administrative activities. The accounting policies of the segment are the same as those described in the Summary of Significant Accounting Policies for the Company. Refer to Note 1 for additional information.

 

The Chief Executive Officer (“CEO”) has been identified as our Chief Operating Decision Maker (“CODM”). The Company manages operations on a company-wide basis, thereby making determinations as to the allocation of resources as one segment. The CODM uses consolidated single-segment financial information to assess performance for the segment and decides how to allocate resources based on the Company’s consolidated net income (loss), which is reported on the Consolidated Statement of Operations. The measure of segment assets is reported on the Consolidated Balance Sheet as total assets.

 

Products from which the reportable segment derives its revenue

 

Lifeway’s primary product is drinkable kefir. The Company manufactures (directly or through a co-manufacturer) and markets products under the Lifeway, Fresh Made, and GlenOaks Farms brand names, as well as under private labels on behalf of certain customers.

 

 

 

 16 

 

 

The Company’s product categories are:

 

  · Drinkable kefir, a cultured dairy product sold in a variety of organic and non-organic sizes, flavors, and types.
  · European-style soft cheeses, including farmer cheese, white cheese, and Sweet Kiss.
  · Cream and other, which primarily consists of cream, a byproduct of raw milk processing.
  · Drinkable yogurt, sold in a variety of sizes and flavors.
  · Other dairy, which primarily consists of butter and sour cream.

 

Net sales of products by category were as follows for the six months ended June 30:

                
   2026   2025 
In thousands  $   %   $   % 
                 
Drinkable Kefir   114,829    88%    85,554    85% 
Cheese   9,338    7%    7,811    8% 
Cream and other   3,935    3%    4,825    5% 
Drinkable Yogurt   1,260    1%    1,083    1% 
Other dairy   543    1%    719    1% 
Net Sales   129,905    100%    99,992    100% 

 

Net sales of products by category were as follows for the three months ended June 30:

                 
   2026   2025 
In thousands  $   %   $   % 
                 
Drinkable Kefir   59,414    89%    46,758    86% 
Cheese   4,654    7%    3,999    8% 
Cream and other   1,886    3%    2,366    4% 
Drinkable Yogurt   676    1%    449    1% 
Other dairy   263    %    329    1% 
Net Sales   66,893    100%    53,901    100% 

 

Beginning in the second quarter of 2026, ProBugs Kefir net sales are included in Drinkable Kefir. Prior period amounts have been reclassified in the three and six-month tables above.

 

Significant Customers

 

Sales are predominately to companies in the retail food industry located within the United States. Two major customers accounted for a total of 25% of net sales for the six months ended June 30, 2026 and 2025. Two major customers accounted for a total of 25% of net sales for the three months ended June 30, 2026 and 2025.

 

 

 

 17 

 

 

Geographic Information

 

Net sales outside the of the United States represented less than 1% of total consolidated net sales for the six and three months ended June 30, 2026 and 2025. Net sales are determined based on the destination where the products are shipped by Lifeway.

 

All the Company’s long-lived assets are in the United States.

 

Note 14 – Shareholder Rights Plan

 

On June 5, 2026, the board of directors authorized and directed the Company to redeem rights of shareholders outstanding on June 5, 2026 to a dividend of Series A Junior Participating Preferred Stock (the “Rights”) declared pursuant to that certain Shareholder Rights Agreement with Computershare Trust Company, N.A., as rights agent dated November 4, 2024, as amended (as amended from time to time, the “Rights Agreement”). Upon such redemption, the Rights will terminate and the only right thereafter of the holders of Rights shall be to receive the redemption price of $0.001 for each Right so held and the Rights Agreement will terminate and be of no further force or effect.

 

Note 15 – Organic Milk Supply

 

To increase the supply of organic milk available to the Company for the manufacture of finished goods, the Company purchased mature dairy cows (or the “herd”) which will be managed by a third-party dairy facility (the “Dairy”), and entered into a supply and purchase agreement (“SPA”) with a COOP (the “COOP”) to purchase the milk produced by the herd. The Company purchased 799 mature dairy cows during 2025 for $2,870.

 

On September 15, 2025, the Company entered into the First Amended Herd Agreement (the “Herd Agreement”) with the Dairy who will manage care of the herd, milk the herd, and sell the milk to the COOP under the SPA, with a right to purchase the herd at the end of the sixty-month agreement period for a nominal amount. Beginning December 1, 2025, the Dairy will make monthly payments to Lifeway over the five year agreement period in exchange for its right to possess and control the herd, including the right to sell milk produced by the herd to the COOP.

 

On June 30, 2026, the Company entered into the Second Amended Herd Agreement with the Dairy, with an effective date (“effective date”) of April 1, 2026. The Second Amendment, among other things, (1) modifies the agreement period to thirty-six months from the effective date, and (2) modifies the monthly payment amount to Lifeway over the thirty-six month agreement period.

 

The herd agreement is treated as a sale of non-financial assets to a party that is not a customer. The Company will recognize a sale upon the delivery of each herd to the Dairy, with interest income recognized over the agreement period. The Company has recorded $830 in prepaid and other current assets and $1,836 in other assets as of June 30, 2026 related to the herd agreement with no recorded gain or loss on sale during 2026 or 2025. The Company records the purchases of dairy cows as investing outflows, principal payments received as investing inflows, and interest income as operating inflows on the statement of cash flows.

 

 

 

 

 18 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) in this Form 10-Q is provided as a supplement to, and should be read in conjunction with, our audited consolidated financial statements, the accompanying notes, and the MD&A included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”). Unless otherwise specified, any description of “our”, “we”, and “us” in this MD&A refer to Lifeway Foods, Inc. (“Lifeway”) and our wholly-owned subsidiaries.

 

Cautionary Statement Regarding Forward-Looking Statements

 

In addition to historical information, this quarterly report contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “anticipate,” “from time to time,” “intend,” “plan,” “ongoing,” “realize,” “should,” “may,” “could,” “believe,” “future,” “depend,” “expect,” “will,” “result,” “can,” “remain,” “assurance,” “subject to,” “require,” “limit,” “impose,” “guarantee,” “restrict,” “continue,” “become,” “predict,” “likely,” “opportunities,” “effect,” “change,” “predict,” and “estimate,” and similar terms or terminology, or the negative of such terms or other comparable terminology. Examples of forward-looking statements include, among others, statements we make regarding:

 

  · Expectations of the effect on our financial condition of claims, litigation, environmental costs, contingent liabilities and governmental and regulatory investigations and proceedings, if any;
  · Strategy for acquisitions, customer retention, growth, product development, market position, financial results and reserves;
  · Estimates of the amounts of sales allowances and discounts to our customers and consumers;
  · Our belief that we will maintain compliance with our loan agreements and have sufficient liquidity to fund our business operations.

 

Forward looking statements are based on management’s beliefs, assumptions, estimates and observations of future events based on information available to our management at the time the statements are made and include any statements that do not relate to any historical or current fact. These statements are not guarantees of future performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may differ materially from what is expressed, implied or forecast by our forward-looking statements due in part to the risks, uncertainties, and assumptions that include:

 

  · Changes in the pricing of commodities;
  · The actions and decisions of our competitors and customers, including those related to price competition;
  · Our ability to successfully implement our business strategy;
  · The effects of government regulation;
  · Disruptions to our supply chain, or our manufacturing and distribution capabilities, including those due to cybersecurity threats;
  · Adverse economic conditions in the United States, our primary market, or any of the other jurisdictions in which we conduct significant business in the future, and resultant changes in consumer spending; and
  · Such other factors as discussed throughout Part I, Item 1 “Business”; Part I, Item 1A “Risk Factors”; and Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2025, Part II, Item 1A of this Form 10-Q and that are described from time to time in our other periodic reports filed with the SEC.

 

These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors could also have material adverse effects on future results. The Company intends these forward-looking statements to speak only at the date made. Except as otherwise required to be disclosed in periodic reports required to be filed by public companies with the SEC pursuant to the SEC’s rules, Lifeway has no duty to update these statements, and it undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

 

 

 19 

 

 

Business Overview

 

Lifeway was founded in 1986 by Michael Smolyansky, ten years after he and his family emigrated from Eastern Europe to the United States. Lifeway was the first to successfully introduce kefir to the U.S. consumer on a commercial scale, initially catering to ethnic consumers in the Chicago, Illinois metropolitan area. Lifeway has grown to become the largest producer and marketer of kefir in the U.S. and an important player in the broader market spaces of probiotic-based products and natural, “better for you” foods.

 

Our primary product is drinkable kefir, a cultured dairy product. Lifeway Kefir is tart and tangy, high in protein, calcium and vitamin D. The Company manufactures (directly or through a co-manufacturer) and markets products under the Lifeway, Fresh Made, and GlenOaks Farms brand names, as well as under private labels on behalf of certain customers.

 

The Company’s product categories are:

 

  · Drinkable Kefir, a cultured dairy product sold in a variety of organic and non-organic sizes, flavors, and types.
  · European-style soft cheeses, including farmer cheese, white cheese, and Sweet Kiss.
  · Cream and other, which primarily consists of cream, a byproduct of raw milk processing.
  · Drinkable Yogurt, sold in a variety of sizes and flavors.
  · Other Dairy, which primarily consists of butter and sour cream.

 

Recent Developments

 

Danone Offering

 

On May 14, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with BTIG, LLC (the “Underwriter”) and Danone USA Public Benefit Corporation (the “Selling Stockholder”) in connection with a public offering of an aggregate of 3,454,756 shares (the “Shares”) of the Company’s common stock, no par value, by the Selling Stockholder at a price to the public of $19.50 per share (the “Offering”).

 

The Offering was completed on May 19, 2026 and was made pursuant to a shelf registration statement on Form S-3 (No. 333-291148) that was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective by the SEC on December 10, 2025 and a prospectus supplement. The Company did not receive any proceeds from the Offering.

 

Share Buyback

 

The Company repurchased 253,153 Shares in the Offering at the same per share price paid by investors in the Offering.

 

Rights Redemption

 

On June 5, 2026, the board of directors authorized and directed the Company to redeem rights of shareholders outstanding on June 5, 2026 to a dividend of Series A Junior Participating Preferred Stock (the “Rights”) declared pursuant to that certain Shareholder Rights Agreement with Computershare Trust Company, N.A., as rights agent dated November 4, 2024, as amended (as amended from time to time, the “Rights Agreement”). Upon such redemption, the Rights will terminate and the only right thereafter of the holders of Rights shall be to receive the redemption price of $0.001 for each Right so held and the Rights Agreement will terminate and be of no further force or effect.

 

Interim Funding Agreement

 

On June 30, 2026, the Company entered into a Master Security Agreement (the “MSA”) with its current lender. The MSA provides for loan advances under an Interim Funding Agreement (the “Interim Funding Agreement”) to finance or refinance the acquisition of equipment, subject to lender’s acceptance of collateral documentation, up to $22,000,000 in the aggregate, during an interim funding period which expires June 30, 2027. Interest on the loan advances is payable monthly in arrears at the 1-month Term SOFR plus 1.65%.

 

Upon the conclusion of loan advances under the Interim Funding Agreement, and the execution of a Collateral Schedule by lender and Lifeway, all loan advances outstanding on the date of such Collateral Schedule (the “Conversion Date”), shall be converted into the Equipment Guidance Line Note (the “Note”). The note is payable in monthly installments of principal and interest and matures five years after the Conversion Date. Interest is payable monthly in arrears at the 1-month Term SOFR plus 1.65%.

 

 

 

 20 

 

 

Business Trends

 

Current Macroeconomic Environment

 

During the second quarter of 2026 we experienced significant increases in the price of conventional milk. We anticipate the elevated pricing to continue into the third quarter and then begin to decrease in the fourth quarter of 2026. Additionally, driven by the rising price of oil, the input cost of our resin-based packaging components such as bottles and caps increased during the second quarter of 2026. We continue to monitor macroeconomic conditions and global trade developments, including inflation in key input costs, implemented tariffs, and the potential for additional or modified tariffs or export controls. These evolving global trade policies may contribute to increased supply chain complexity, further commodity cost volatility, and broader economic uncertainty.

 

We do not currently expect tariffs to have a material adverse impact on our operations or financial results. We are primarily a United States based manufacturer sourcing a vast majority of our inputs domestically. In addition, all our domestically produced products are sold to customers in the United States. We expect the accelerating consumer focus on health and wellness to drive increased demand for our products.

 

Results of Operations

 

Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025

 

The following table presents certain information concerning our financial results, including information presented as a percentage of consolidated net sales:

 

   Three Months Ended June 30, 
   2026   2025 
   $   %   $   % 
Net sales   66,893    100.0%    53,901    100.0% 
                     
Cost of goods sold   52,859    79.0%    37,669    69.9% 
Depreciation expense   1,008    1.5%    832    1.5% 
Total cost of goods sold   53,867    80.5%    38,501    71.4% 
                     
Gross profit   13,026    19.5%    15,400    28.6% 
                     
Selling expenses   7,634    11.4%    4,718    8.8% 
General & administrative expense   4,657    7.0%    4,752    8.8% 
Amortization expense   135    0.2%    135    0.3% 
Total operating expenses   12,426    18.6%    9,605    17.9% 
                     
Income from operations   600    0.9%    5,795    10.7% 
                     
Other income (expense):                    
Interest expense   (215)   (0.3%)   (21)   0.0% 
Gain on sales of investments       0.0%    55    0.1% 
Other income (expense), net   22    0.0%    82    0.2% 
Total other income (expense)   (193)   (0.3%)   116    0.3% 
                     
Income before provision for income taxes   407    0.6%    5,911    11.0% 
                     
Provision for income taxes   280    0.4%    1,662    3.1% 
                     
Net income   127    0.2%    4,249    7.9% 

 

 

 21 

 

 

Net Sales

 

Net sales were at $66,893 for the three-month period ended June 30, 2026, an increase of $12,992 or 24.1% versus prior year. The net sales increase was primarily driven by higher volumes of our branded drinkable kefir.

 

Gross Profit

Gross profit as a percentage of net sales was 19.5% and 28.6% in the three-month period ended June 30, 2026 and 2025, respectively. The decrease versus the prior year was driven by the unfavorable impact of milk pricing and to a lesser extent the unfavorable impact of resin-based packaging inputs and transportation costs.

 

Selling Expenses

 

Selling expenses increased by $2,916 to $7,634 during the three-month period ended June 30, 2026 from $4,718 during the same period in 2025. Selling expenses as a percentage of net sales increased to 11.4% in the three-month period ended June 30, 2026 from 8.8% during the same period in 2025. The increase is primarily a result of our continued investments in marketing activities to drive brand awareness and sales volumes.

 

General and Administrative Expenses

 

General and administrative expenses increased $95 to $4,657 during the three-month period ended June 30, 2026 from $4,752 during the same period in 2025. General and administrative expenses as a percentage of net sales decreased to 7.0% in the three-month period ended June 30, 2026 from 8.8% during the same period in 2025. During the second quarter of 2026, the Company incurred approximately $375 of legal and professional fees associated with the sale of Danone USA Public Benefit Corporation's holdings of common stock of Lifeway Foods, Inc. in an underwritten transaction.

 

Provision for Income Taxes

 

Income taxes were recognized at effective rates of 68.7% and 28.1% for the three months ended June 30, 2026 and 2025, respectively. Statutory Federal and state tax rates remained consistent from 2025 to 2026. The Company has items that are nondeductible or are discrete adjustments to tax expense. The Company consistently reflects non-deductible officer compensation expense, non-deductible stock-based compensation expense and separate state tax rates from period to period. Although similar items were reflected in 2026, the percentage effect is different due to the difference in pre-tax income in 2026 compared to 2025.

 

The Company’s effective tax rate may change from period to period based on recurring and non-recurring factors including the relative mix of pre-tax earnings (or losses), the jurisdictional mix of earnings, enacted tax legislation, state income taxes, the impact of non-deductible items, changes in valuation allowances, settlement of tax audits, and the expiration of the statute of limitations in relation to unrecognized tax benefits. The Company records discrete income tax items such as enacted tax rate changes and completed tax audits in the period in which they occur.

 

Income taxes are discussed in Note 10 in the Notes to the Consolidated Financial Statements.

 

 

 

 22 

 

 

Six Months Ended June 30, 2026 Compared to Six Months Ended June 30, 2025

 

The following table presents certain information concerning our financial results, including information presented as a percentage of consolidated net sales:

 

   Six Months Ended June 30, 
   2026   2025 
   $   %   $   % 
Net sales   129,905    100.0%    99,992    100.0% 
                     
Cost of goods sold   97,600    75.1%    71,923    71.9% 
Depreciation expense   1,928    1.5%    1,634    1.6% 
Total cost of goods sold   99,528    76.6%    73,557    73.5% 
                     
Gross profit   30,377    23.4%    26,435    26.5% 
                     
Selling expense   13,822    10.6%    9,416    9.4% 
General & administrative expense   9,360    7.2%    9,380    9.4% 
Amortization expense   270    0.2%    270    0.3% 
Total operating expenses   23,452    18.0%    19,066    19.1% 
                     
Income from operations   6,925    5.4%    7,369    7.4% 
                     
Other income (expense):                    
Interest expense   (283)   (0.2%)   (35)   0.0% 
Fair value loss on investments       0.0%    (20)   0.0% 
Gain on investments       0.0%    3,407    3.4% 
Other income (expense), net   22    0.0%    156    0.2% 
Total other income (expense)   (261)   (0.2%)   3,508    3.6% 
                     
Income before provision for income taxes   6,664    5.2%    10,877    11.0% 
                     
Provision for income taxes   1,863    1.4%    3,088    3.1% 
                     
Net income   4,801    3.8%    7,789    7.9% 

 

Net Sales

 

Net sales were at $129,905 for the six-month period ended June 30, 2026, an increase of $29,913 or 29.9% versus prior year. The net sales increase was primarily driven by higher volumes of our branded drinkable kefir.

 

Gross Profit

 

Gross profit as a percentage of net sales was 23.4% and 26.5% during the six-month period ended June 30, 2026 and 2025, respectively. The decrease versus the prior year was driven by the unfavorable impact of milk pricing and to a lesser extent the unfavorable impact of resin-based packaging inputs and transportation costs, partially offset by higher volumes of our branded products, which provided manufacturing efficiencies.

 

 

 

 23 

 

 

Selling Expense

 

Selling expense increased by $4,406 to $13,822 during the six-month period ended June 30, 2026 from $9,416 during the same period in 2025. Selling expenses as a percentage of net sales increased to 10.6% in the six-month period ended June 30, 2026 from 9.4% during the same period in 2025. The increase is primarily a result of our continued investments in marketing activities to drive brand awareness and sales volumes.

 

General and Administrative Expense

 

General and administrative expense decreased $20 to $9,360 during the six-month period ended June 30, 2026 from $9,380 during the same period in 2025. The Company incurred approximately $375 of legal and professional fees associated with the sale of Danone USA Public Benefit Corporation's holdings of common stock of Lifeway Foods, Inc. in an underwritten transaction during the six-month period ended June 30, 2026.

 

Provision for Income Taxes

 

The effective income tax rate for the six months ended June 30, 2026 was 28.0% compared to 28.4% in the same period last year. The change in the Company’s effective tax rate is primarily driven by the decrease in pre-tax book income and changes in the amount of non-deductible officer compensation and non-deductible stock-based compensation expense.

 

The Company’s effective tax rate may change from period to period based on recurring and non-recurring factors including the relative mix of pre-tax earnings (or losses), the jurisdictional mix of earnings, enacted tax legislation, state income taxes, the impact of non-deductible items, changes in valuation allowances, settlement of tax audits, and the expiration of the statute of limitations in relation to unrecognized tax benefits. The Company records discrete income tax items such as enacted tax rate changes and completed tax audits in the period in which they occur.

 

Income taxes are discussed in Note 10 in the Notes to the Consolidated Financial Statements.

 

Liquidity and Capital Resources

 

Management assesses the Company’s liquidity in terms of its ability to generate cash to fund its operating, investing, and financing activities. The Company remains in a strong financial position, and believes that its cash flow from operations, revolving credit facility, interim funding agreement, and cash and cash equivalents will continue to provide sufficient liquidity for its working capital needs, capital resource requirements, and growth initiatives and to ensure the continuation of the Company as a going concern.

 

If additional borrowings are needed, $3,000 was available under the Revolving Credit Facility and $22,000 was available under the Interim Funding Agreement as of June 30, 2026 (see Note 7, Debt).

 

We are in compliance with the terms of the Credit Agreement and expect to meet foreseeable financial requirements. The success of our business and financing strategies will continue to provide us with the financial flexibility to take advantage of various opportunities as they arise. To date, we have been successful in generating cash and obtaining financing as needed. However, if a serious economic or credit market crisis ensues, it could have a negative effect on our liquidity, results of operations and financial condition.

 

The Company’s most significant ongoing short-term cash requirements relate primarily to funding operations (including expenditures for raw materials, labor, manufacturing and distribution, trade and promotions, advertising and marketing, and tax liabilities) as well as expenditures for property, plant and equipment.

 

Long-term cash requirements primarily relate to funding long-term debt repayments (see Note 7, Debt) and deferred income taxes (see Note 10, Income Taxes, in our Annual Report on Form 10-K).

 

 

 

 24 

 

 

Cash Flow

 

The following table is derived from our Consolidated Statement of Cash Flows:

 

   Six months Ended
June 30,
 
Net Cash Flows Provided By (Used In):  2026   2025 
Operating activities  $4,039   $3,762 
Investing activities  $(19,282)  $795 
Financing activities  $16,759   $(65)

 

Operating Activities

 

Net cash provided by operating activities was $4,039 and $3,762 during the six-month period ended June 30, 2026 and 2025, respectively. The increase was primarily due to the increase in cash earnings offset by the change in working capital.

 

Investing Activities

 

Net cash used in investing activities was $19,282 during the six-month period ended June 30, 2026 compared to net cash provided by investing activities of $795 in the same period in 2025.

 

The increase in purchases of property and equipment is primarily driven by the expansion of manufacturing capacity and modernization of our Waukesha, Wisconsin facility. This project will enable Lifeway to meet increasing sales demand and will double the facility’s manufacturing capacity and improve packaging efficiency, as well as other operational improvements. The Company currently estimates investing approximately $50,500. As of June 30, 2026, $38,917 is included on the consolidated balance sheet in property, plant and equipment, with $3,691 in-service and recorded in machinery and equipment, $7,348 in-service and recorded in leasehold improvements, and $27,878 recorded in construction in process. The cumulative cash paid for this project is $38,917 as of June 30, 2026. The project will be funded primarily through cash on-hand and cash flow from operations, with further requirements available under the Company’s revolving credit facility and interim funding agreement. The ability to manufacture and package at the increased scale is expected to begin in January 2027, and the total project expected to be completed during the first fiscal quarter of 2027.

 

The Company received cash proceeds of $5,152 in the first quarter of 2025 from the sale of our Simple Mills investment.

 

Our capital spending is focused on three core areas: growth, cost reduction, and facility improvements. Growth capital spending supports capacity expansion and new product innovation and enhancements. Cost reduction and facility improvements support manufacturing efficiency, safety, and productivity. We continue to make capital expenditures primarily to modernize manufacturing facilities and support productivity initiatives.

 

Financing Activities

 

Net cash provided by financing activities was $16,759 during the six-month period ended June 30, 2026 compared to net cash used in financing activities of $65 in the same period in 2025. The cash provided during 2026 primarily represents the line of credit borrowing in connection with the Waukesha Wisconsin facility expansion and modernization project. During the second quarter of 2026, the Company repurchased $4,937 of treasury stock in connection with the sale of Danone USA Public Benefit Corporation's holdings of common stock of Lifeway Foods, Inc. in an underwritten transaction. During the first quarter of 2026, to comply with the Company’s contractual obligations in place at the time prohibiting the Company from issuing equity to the Chief Executive Officer and certain of her affiliates, the Company settled previously vested restricted stock units held by the Chief Executive Officer in cash. The cash used in 2025 represented credit agreement amendment expenses incurred during the first quarter.

 

 

 

 25 

 

 

Debt Obligations

 

As of June 30, 2026, the Company had $22,000 outstanding under the Revolving Credit Facility. The Company had $3,000 available for future borrowings under the Revolving Credit Facility as of June 30, 2026.

 

All outstanding amounts under the revolving line of credit bear interest at the Secured Overnight Financing Rate (“SOFR”), plus 1.75% (5.48% as of June 30, 2026). Interest is payable monthly in arrears. Lifeway is also required to pay a quarterly unused line fee of 0.25% on the Revolving Credit Facility, and in conjunction with the issuance of any letters of credit, a letter of credit fee of 1.00%.

 

As of June 30, 2026, the Company had $0 outstanding under the Interim Funding Agreement. The Company had $22,000 available for future borrowings under the Interim Funding Agreement as of June 30, 2026, subject to lender’s acceptance of collateral documentation.

 

All outstanding amounts under the Interim Funding Agreement bear interest at the 1-month Term Secured Overnight Financing Rate (“SOFR”), plus 1.65%. Monthly Interest is payable monthly in arrears.

 

The Credit Agreement includes customary representations, warranties, and covenants, including financial covenants requiring the Company to maintain a fixed charge coverage ratio of no less than 1.25 to 1.00, and a maximum cash flow leverage ratio of no greater than 2.00 to 1.00.

 

The Company is in compliance with all applicable financial debt covenants as of June 30, 2026. See Note 7 to our Consolidated Financial Statements for additional information regarding our indebtedness and related agreements.

 

Recent Accounting Pronouncements

 

Information regarding recent accounting pronouncements is provided in Note 2 – Summary of Significant Accounting Policies.

 

Critical Accounting Policies and Estimates

 

A description of the Company’s critical accounting policies and estimates is contained in its Annual Report on Form 10-K for the year ended December 31, 2025. There were no material changes to the Company’s critical accounting policies and estimates in the six months ended June 30, 2026.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

The Company has established disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (“SEC”), and such information is accumulated and communicated to management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosure. Management, together with our CEO and CFO, evaluated the effectiveness of the Company’s disclosure controls and procedures as of June 30, 2026. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of June 30, 2026.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the quarter ended June 30, 2026 that has materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 26 

 

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

Information regarding legal proceedings is available in Note 9, Commitment and Contingencies.

 

ITEM 1A. RISK FACTORS.

 

There have been no material changes from the risk factors disclosed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

Issuer Purchases of Equity Securities

  

Period  Total number of shares purchased   Average price paid per share   Total number of shares purchased as part of a publicly announced program (a)   Approximate Dollar Value of Shares that may yet be Purchased Under the Plans or Programs
($ in thousands)
(a)
 
                 
4/1/2026 to 4/30/2026      $         –   $           – 
5/1/2026 to 5/31/2026   253,156   $19.50       $ 
6/1/2026 to 6/30/2026      $       $ 
Fiscal Year 2026   253,153   $19.50       $ 

 

(a) On May 14, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with BTIG, LLC (the “Underwriter”) and Danone USA Public Benefit Corporation (the “Selling Stockholder”) in connection with a public offering of an aggregate of 3,454,756 shares (the “Shares”) of the Company’s common stock, no par value, by the Selling Stockholder at a price to the public of $19.50 per share (the “Offering”). The Offering was completed on May 19, 2026. The Company repurchased 253,153 Shares in the Offering at the same per share price to be paid by investors in the Offering.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 5. OTHER INFORMATION.

 

During the quarter ended June 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.

 

 

 

 27 

 

 

ITEM 6. EXHIBITS.

 

No.   Description   Form   Period Ending   Exhibit   Filing Date
                     
10.1   Master Security Agreement, Interim Funding Agreement, and Equipment Guidance Line Note, dated as of June 30, 2026 by and among Lifeway Foods, Inc. and CIBC Bank USA, as Lender.   8-K   6/30/26   10.1   7/7/26
                     
31.1   Rule 13a-14(a)/15d-14(a) Certification of Julie Smolyansky   Filed Herewith            
                     
31.2   Rule 13a-14(a)/15d-14(a) Certification of Eric Hanson   Filed Herewith            
                     
32.1   Section 1350 Certification of Julie Smolyansky*   Furnished Herewith            
                     
32.2   Section 1350 Certification of Eric Hanson*   Furnished Herewith            

 

101.INS   Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).

 

* The exhibits deemed furnished with this Form 10-Q and are not deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act., whether made before or after the date of the filing of this Form 10-Q and irrespective of any general incorporation language contained in such filing.

 

 

 

 

 28 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  LIFEWAY FOODS, INC.
   
   
     
Date: August 13, 2026 By: /s/ Julie Smolyansky
    Julie Smolyansky
    Chief Executive Officer, President, and Director
    (Principal Executive Officer)
     
     
     
Date: August 13, 2026 By: /s/ Eric Hanson
    Eric Hanson
    Chief Financial & Accounting Officer
    (Principal Financial and Accounting Officer)

 

 

 

 

 

 29